Vaxcyte says Phase 3 OPUS-1 trial of VAX-31 meets primary endpoints in adults versus Prevnar 20, Capvaxive

• Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine.
• The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US.
• Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them.
• Safety and tolerability were broadly similar to existing comparator vaccines in the trial.
• Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050600PRIMZONEFULLFEED9839330) on October 05, 2026, and is solely responsible for the information contained therein.